College Station, TX, United States of America

Margarita Martinez-Moczygemba

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Immune Modulation by Margarita Martinez-Moczygemba

Introduction

Margarita Martinez-Moczygemba is a notable inventor based in College Station, TX (US). She has made significant contributions to the field of immune modulation, particularly in addressing allergic responses. Her work is crucial for developing new therapeutic strategies for conditions such as allergic asthma and allergic rhinitis.

Latest Patents

Margarita holds a patent titled "Methods and compositions for adaptive immune modulation." This patent focuses on methods and compositions designed to modulate an immune response, specifically targeting type I hypersensitivity responses. The research demonstrates that aerosol administration of TLR agonists, particularly a combination of TLR2/6 and TLR9 agonists along with an antigen, can effectively suppress the immune response. This is exemplified by the reduction of antigen-specific IgE production and a decrease in airway eosinophils in bronchoalveolar lavage fluid in response to immunization.

Career Highlights

Margarita is affiliated with the University of Texas System, where she continues her research and innovation in immune modulation. Her work has the potential to lead to significant advancements in treating allergic conditions, improving the quality of life for many individuals affected by these diseases.

Collaborations

Margarita has collaborated with esteemed colleagues such as Burton F Dickey and Michael J Tuvim. These collaborations have enriched her research and contributed to the development of innovative solutions in her field.

Conclusion

Margarita Martinez-Moczygemba's contributions to immune modulation represent a significant advancement in medical science. Her innovative approaches and dedication to research continue to pave the way for new treatments for allergic conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…